Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Makoto HibinoYoshinori ImamuraRai ShimoyamaTomoya FukuiRyuta FukaiAkihiko IwaseYukihiro TamuraYusuke ChiharaTakafumi OkabeKiyoaki UryuTadahisa OkudaMasataka TaguriHironobu MinamiPublished in: Targeted oncology (2024)
This study was registered at the University Hospital Medical Information Network Clinical Trials Registry on 9 March, 2023 (identification UMIN000050552).